Shedding Light on Laser Therapy: How It Works and When It Helps

Regulatory Tightening on Laser Devices

Laser therapy, particularly low-level laser therapy (LLLT) or photobiomodulation (PBM), applies low-intensity light to stimulate cellular processes without generating heat. It targets pain relief, inflammation reduction, and accelerated healing in conditions ranging from musculoskeletal injuries to post-surgical recovery and chronic issues like knee osteoarthritis.

In January 2026, the FDA updated its General Wellness: Policy for Low Risk Devices guidance. The change clarifies that products using higher-risk technologies—such as lasers claiming skin rejuvenation but carrying risks of burns to skin or eyes—no longer qualify for the low-risk, non-device regulatory pathway. Instead, they fall under formal medical device requirements, including premarket review. This directly impacts a segment of the expanding consumer and clinical laser market.

The timing coincides with accelerating adoption and market growth. The cold laser therapy sector sees heavy investment in FDA-cleared devices, with applications expanding into neurodegenerative conditions and broader therapeutic indications. Recent randomized trials, including a 2025 study on knee osteoarthritis, demonstrate significant pain reduction and functional improvements using specific wavelengths and doses.

Yet non-obvious tensions remain. While evidence accumulates for targeted uses, the field struggles with protocol standardization—varying wavelengths, energies, and application methods across studies. Reimbursement stays patchy; most U.S. applications lack formal coverage, unlike in some other countries. The FDA's move heightens risks for manufacturers and providers of borderline wellness devices, potentially raising costs passed to patients or limiting options.

Stakeholders face concrete consequences: companies must navigate added compliance burdens or withdraw products, while clinicians weigh evidence against regulatory uncertainty in an era of rising demand for non-invasive alternatives to opioids or surgery.